Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 346s Year: 2004
Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life Source: Eur Respir J 2003; 22: Suppl. 45, 51s Year: 2003
Superior efficacy of a low daily dose of a new fixed combination of beclometasone dipropionate/formoterol pMDI compared to an increased daily dose of BDP in moderate persistent asthma: a 3 month clinical study Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Achieving guideline-based asthma control: does the patient benefit? Source: Eur Respir J 2002; 20: 588-596 Year: 2002
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Is overall asthma control being achieved? A hypothesis-generating study Source: Eur Respir J 2001; 17: 589-595 Year: 2001
The cost-effectiveness of achieving asthma control with the combination products salmeterol/fluticasone propionate or formoterol/budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 159s Year: 2001
Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Aiming for total control of asthma with salmeterol/fluticasone propionate (SFC), a cost effective option Source: Eur Respir J 2005; 26: Suppl. 49, 430s Year: 2005
Salmeterol/fluticasone propionate combination (SFC) inhaler is associated with greater levels of compliance in children than other regular asthma medications Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Long-term clinical management with the salmeterol/fluticasone propionate combination, fluticasone propionate and sameterol in a 'real-life' study Source: Eur Respir J 2003; 22: Suppl. 45, 236s Year: 2003
Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Budesonide/formoterol in a single inhaler once or twice daily provides better asthma control than inhaled fluticasone or budesonide alone in patients with moderate persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002